“but we would expect that that overhang here clears here certainly in the next, you know, six to twelve months.”

In context

“it delays of new orders? Just sort of how are you seeing those dynamics play out? And do you expect a recovery in that or improvement in that as we go through the rest of the year and we have sort of continued discussion on the tariff front? Thanks. Rainer Blair: So, Mike, I mean, I think there's a general overlay here of trade uncertainty as it relates to how the tariffs will play out. If we think about the different end markets, in pharma, certainly, as we pointed out, this market continues to grow. Over time, there is going to be a need for capacity expansions. And now pharma companies have to ask themselves the critical question as to where they're going to build that new capacity. Of course, that's hard to do if you don't know yet what the tariff situation ultimately plays out to be, but we would expect that that overhang here clears here certainly in the next, you know, six to twelve months. That certainly our planning assumption. So that is an overlay on pharma. As it relates to the applied and clinical market. I think that's less of a factor. So clinical markets we see volumes remaining fairly consistent capacity increases are more incremental. In that regard. And as it relates to applied markets, I would say the same thing. Great. Thanks. I'll leave that. Margaux: And we'll next go to Doug Schnickner with Wolfe Research. Please go ahead. Doug Schenkel: Good morning. Matt and Matt, congrats, and thanks for all the help. And thanks for the broader team for giving us some time this morning. So I just want to talk about Bioprocess a little bit more. And I really just want to clarify your bioprocessing assumptions that are embedded into guidance. So first, you had previously to”